N-cyano-N'-(4-acetamidophenyl)-O-phenylisourea | 700805-27-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-cyano-N'-(4-acetamidophenyl)-O-phenylisourea
• 英文别名: phenyl N'-(4-acetamidophenyl)-N-cyanocarbamimidate
• CAS: 700805-27-2
• 化学式: C₁₆H₁₄N₄O₂
• 分子量: 294.313
• InChiKey: LTZYHLNOPQIYQP-UHFFFAOYSA-N

物化性质

• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  86.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-肼吡啶 、 N-cyano-N'-(4-acetamidophenyl)-O-phenylisourea 生成 N-[4-(5-amino-1-pyridin-2-yl-1H-[1,2,4]triazol-3-ylamino)-phenyl]-acetamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia

  摘要：

  A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optimized for both potency against FLT3 and FLT3/c-KIT and excellent potency in cell-based assays, leading to dose-dependent cell death in acute myelogenous leukemia (AML) patient blast samples. Ultimately, the AML patient blast data defined the preferred target profile as we designed and evaluated a set of FLT3 selective and FLT3/c-KIT dual molecules. Further optimization for pharmacokinetic properties resulted in the selection of the dual FLT3/c-KIT inhibitor, N-3-(4-(trans-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine, VX-322 (compound 37), to move forward to preclinical evaluation.

  DOI：

  10.1021/jm200712h
• 作为产物：
  描述：

  N-氰基羰亚胺二苯基酯 、 4′-氨基乙酰苯胺 以 异丙醇 为溶剂， 生成 N-cyano-N'-(4-acetamidophenyl)-O-phenylisourea
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of a Novel Dual Fms-Like Tyrosine Kinase 3/Stem Cell Factor Receptor (FLT3/c-KIT) Inhibitor for the Treatment of Acute Myelogenous Leukemia

  摘要：

  A high-throughput screen of our compound archive revealed a novel class of dual FMS-like tyrosine kinase 3 (FLT3)/c-KIT inhibitors. With the help of molecular modeling, this class was rapidly optimized for both potency against FLT3 and FLT3/c-KIT and excellent potency in cell-based assays, leading to dose-dependent cell death in acute myelogenous leukemia (AML) patient blast samples. Ultimately, the AML patient blast data defined the preferred target profile as we designed and evaluated a set of FLT3 selective and FLT3/c-KIT dual molecules. Further optimization for pharmacokinetic properties resulted in the selection of the dual FLT3/c-KIT inhibitor, N-3-(4-(trans-4-morpholinocyclohexyl)phenyl)-1-(pyridin-2-yl)-1H-1,2,4-triazole-3,5-diamine, VX-322 (compound 37), to move forward to preclinical evaluation.

  DOI：

  10.1021/jm200712h

文献信息

• Diaminotriazole compounds useful as protein kinase inhibitors
  申请人：Salituro Francesco

  公开号：US20060063756A1

  公开（公告）日：2006-03-23

  The present invention relates to inhibitors of protein kinases, particularly to inhibitors of JAK2 and JAK3. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods of using the compositions in the treatment of various disorders.

  本发明涉及蛋白激酶的抑制剂，特别是JAK2和JAK3的抑制剂。该发明还提供包括该发明化合物的药物组合物，制备该化合物的方法以及在治疗各种疾病中使用该组合物的方法。
• DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1791830A1

  公开（公告）日：2007-06-06
• US7329652B2
  申请人：——

  公开号：US7329652B2

  公开（公告）日：2008-02-12
• [EN] DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS DIAMINOTRIAZOLES UTILES COMME INHIBITEURS DE PROTÉINE KINASES
  申请人：VERTEX PHARMA

  公开号：WO2006034116A1

  公开（公告）日：2006-03-30

  The present invention relates to inhibitors of protein kinases, particularly to inhibitors of JAK2 and JAK3. The invention also provides pharmaceutical compositions comprising the compounds of the invention, processes for preparing the compounds and methods for using the compositions in the treatment of various disorders.